IP Library › Granted Patent US 12,595,441
Granted Patent B2
US 12,595,441 · App. 18/065,645 · Granted Apr 7, 2026

Automatic dishwashing composition comprising a protease

Inventors: Michelle Jackson (Newcastle Upon Tyne, GB); Karolina Anna Korzycka (Gateshead, GB); Carly Pickering (Tyne & Wear, GB); Philip Frank Souter (Morpeth, GB); Viktor Yuryevich Alekseyev (Palo Alto, CA); Lilia Maria Babe (Emerald Hills, CA); Lydia Dankmeyer (Rotterdam, NL); Roopa Santosh Ghirnikar (Sunnyvale, CA); Frits Goedegebuur (Vlaardingen, NL); Thijs Kaper (Half Moon Bay, CA); Harm Jan Mulder (Voorhout, NL); Nils Henning Redestig (Amsterdam, NL); Sander Van Stigt-Thans (Nieuwerkerk aan den IJ ssel, NL)
Assignee: The Procter & Gamble Company
C11D3/38609C11D1/825C11D3/38636
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,595,441
App. No.
18/065,645
Granted
Apr 7, 2026
Kind
B2
Abstract

Fabric and home care compositions including a surfactant and a protease. The automatic dishwashing composition is in the form of a water-soluble unit-dose pouch including a compartment. The compartment includes both a powder component and a gel component. The protease is a subtilisin variant that includes: (i) a mutation at position 122; and (ii) one or more mutations at positions 126, 127, 128, 211 and 212, with reference to SEQ ID NO: 1. The variant has at least about 80% identity to the amino acid sequence of SEQ ID NO: 1.

Claims (25)

1 . An automatic dishwashing composition comprising a surfactant and a protease,

wherein the automatic dishwashing composition is in the form of a water-soluble unit-dose pouch comprising a compartment, wherein the compartment comprises both a powder component and a gel component, and

wherein the protease comprises a subtilisin variant that comprises:

(i) a mutation at position 122; and

(ii) one or more mutations at positions 126, 127, 128, 211 and 212,

with reference to SEQ ID NO: 1,

wherein the subtilisin variant has 88% or more identity to the amino acid sequence of SEQ ID NO: 1.

2 . The composition according to claim 1 , wherein the composition is in the form of a multi-compartment pouch that comprises two or more compartments.

3 . The composition according to claim 1 , wherein the protease is present in the gel component.

4 . The composition according to claim 1 , further comprising a bleach, wherein the bleach is present in the powder component.

5 . The composition according to claim 1 , wherein the subtilisin variant comprises:

(i) the mutation at position M122L; and

(ii) one or more mutations at positions 126, 127, 128, 211 and 212.

6 . The composition according to claim 1 , wherein the subtilisin variant comprises two or more mutations at positions 126, 127, 128, 211 and 212.

7 . The composition according to claim 1 , wherein the subtilisin variant comprises one or more mutations selected from S126A, D127E, F128G, M211Q and N212Q.

8 . The composition according to claim 1 , wherein the subtilisin variant comprises the mutations M122L, S126A, D127E, F128G, M211Q and N212Q.

9 . The composition according to claim 1 , wherein the subtilisin variant comprises an amino acid sequence having 89% sequence identity to the amino acid sequence of SEQ ID NO: 1.

10 . The composition according to claim 1 , wherein the subtilisin variant is derived from a parent or reference polypeptide with at least 60% amino acid sequence identity to SEQ ID NO: 1.

11 . The composition according to claim 1 , wherein the composition further comprises a manganese bleach catalyst selected from the group consisting of 1,4,7-trimethyl-1,4,7-triazacyclononane (Me-TACN), 1,2, 4,7-tetramethyl-1,4,7-triazacyclononane (Me/Me-TACN), and mixtures thereof.

12 . The composition according to claim 1 , wherein the composition further comprises one or more other enzymes selected from acyl transferases, amylases, alpha-amylases, beta-amylases, alpha-galactosidases, arabinases, arabinosidases, aryl esterases, beta-galactosidases, beta-glucanases, carrageenases, catalases, cellulases, chondroitinases, cutinases, dispersins, endo-glucanases, endo-beta-mannanases, exo-beta-mannanases, esterases, exo-mannanases, galactanases, glucoamylases, hemicellulases, hexosaminidase, hyaluronidases, keratinases, laccases, lactases, ligninases, lipases, lipolytic enzymes, lipoxygenases, lysozyme, metalloproteases, mannanases, nucleases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectinases, pentosanases, perhydrolases, peroxidases, PETases, phenoloxidases, phosphatases, phospholipases, phytases, polyesterases, polygalacturonases, additional proteases, pullulanases, reductases, rhamnogalacturonases, tannases, transglutaminases, xylan acetyl-esterases, xylanases, and xylosidases; and combinations thereof.

13 . The composition according to claim 12 , wherein the one or more enzymes comprises an amylase selected from the group consisting of AA707, AA560, AAI10, SP722, BspAmy24, and CspAmy1, variants thereof, and combinations thereof.

14 . The composition according to claim 12 , wherein the one or more enzymes comprises a recombinant, non-naturally-occurring variant of a parent alpha-amylase.

15 . The composition according to claim 1 , wherein the subtilisin variant comprises an amino acid sequence having 89% or more sequence identity to the amino acid sequence of SEQ ID NO: 1.

16 . The composition according to claim 1 , wherein the subtilisin variant comprises an amino acid sequence having 90% sequence identity to the amino acid sequence of SEQ ID NO: 1.

17 . The composition according to claim 1 , wherein the subtilisin variant comprises an amino acid sequence having 90% or more sequence identity to the amino acid sequence of SEQ ID NO: 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2023
From: ALEKSEYEV, VIKTOR YURYEVICH; BABE, LILIA MARIA; GHIRNIKAR, ROOPA SANTOSH; KAPER, THIJS; JACKSON, MICHELLE; KORZYCKA, KAROLINA ANNA; PICKERING, CARLY; SOUTER, PHILIP FRANK; DANKMEYER, LYDIA; GOEDEGEBUUR, FRITS; MULDER, HARM JAN; REDERSTIG, NILS HENNING; VAN STIGT-THANS, SANDER
To: THE PROCTER AND GAMBLE COMPANY
Reel/Frame 065213/0795 →
Continuity (2)
Provisional Application 63290125 · Dec 16, 2021
Related Publication 20240166973A1 · May 23, 2024
References Cited (100)
US 4760025A · Estell · 1988 [cited by applicant]
US 5362414A · Outtrup et al. · 1994 [cited by applicant]
US 5679630A · Baeck · 1997 [cited by applicant]
US 6017871A · Baeck · 2000 [cited by examiner]
US 6165966A · Mciver · 2000 [cited by applicant]
US 6312936B1 · Poulose · 2001 [cited by applicant]
US 9429449B2 · Huang · 2016 [cited by applicant]
US 9493730B2 · Meek · 2016 [cited by applicant]
US 9670436B2 · Jackson · 2017 [cited by applicant]
US 10538721B2 · Dirr · 2020 [cited by examiner]
US 10538722B2 · Gjermansen et al. · 2020 [cited by applicant]
US 10563186B2 · Andersen et al. · 2020 [cited by applicant]
US 10731111B2 · Mole et al. · 2020 [cited by applicant]
US 11473075B2 · Estell et al. · 2022 [cited by applicant]
US 20120149625A1 · Simonsen · 2012 [cited by applicant]
US 20120156733A1 · Cuevas et al. · 2012 [cited by applicant]
US 20140228274A1 · Mikkelsen · 2014 [cited by applicant]
US 20150072913A1 · Aehle et al. · 2015 [cited by applicant]
US 20150080283A1 · Bisgaard-frantzen et al. · 2015 [cited by applicant]
US 20160251641A1 · Svendsen et al. · 2016 [cited by applicant]
US 20170321159A1 · Lant et al. · 2017 [cited by applicant]
US 20200291374A1 · Babe et al. · 2020 [cited by applicant]
US 20220064621A1 · Degering et al. · 2022 [cited by applicant]
US 20220112476A1 · Gao et al. · 2022 [cited by applicant]
US 20220154110A1 · Mussmann et al. · 2022 [cited by applicant]
US 20220204960A1 · Mussmann et al. · 2022 [cited by applicant]
US 20220251477A1 · Weber et al. · 2022 [cited by applicant]
US 20230348879A1 · Cascao-pereira et al. · 2023 [cited by applicant]
US 20230365897A1 · Jackson · 2023 [cited by examiner]
US 20240401017A1 · Shaw et al. · 2024 [cited by applicant]
DE 102006022216A1 · 2007 [cited by applicant]
DE 102006022224A1 · 2007 [cited by applicant]
EP 1022334A2 · 2000 [cited by applicant]
EP 2358857B1 · 2017 [cited by applicant]
WO 8906270A1 · 1989 [cited by applicant]
WO 9217577A1 · 1992 [cited by applicant]
WO 9422800A1 · 1994 [cited by applicant]
WO 9623873A1 · 1996 [cited by applicant]
WO 9700324A1 · 1997 [cited by applicant]
WO 9813458A1 · 1998 [cited by applicant]
WO 0060060A2 · 2000 [cited by applicant]
WO 03054184A1 · 2003 [cited by applicant]
WO 03054185A1 · 2003 [cited by applicant]
WO 03055974A2 · 2003 [cited by applicant]
WO 2004067737A2 · 2004 [cited by applicant]
WO 2005052146A2 · 2005 [cited by applicant]
WO 2005052161A2 · 2005 [cited by applicant]
WO 2005056782A2 · 2005 [cited by applicant]
WO 2006000060A1 · 2006 [cited by applicant]
WO 2006002643A2 · 2006 [cited by applicant]
WO 2007044993A2 · 2007 [cited by applicant]
WO 2007106293A1 · 2007 [cited by applicant]
WO 2008063400A1 · 2008 [cited by applicant]
WO 2008087417A1 · 2008 [cited by applicant]
WO 2008087424A1 · 2008 [cited by applicant]
WO 2008106214A1 · 2008 [cited by applicant]
WO 2008106215A1 · 2008 [cited by applicant]
WO 2009149130A2 · 2009 [cited by applicant]
WO 2009149271A2 · 2009 [cited by applicant]
WO 2011036153A1 · 2011 [cited by applicant]
WO 2011100410A2 · 2011 [cited by applicant]
WO 2013003659A1 · 2013 [cited by applicant]
WO 2014019405A1 · 2014 [cited by applicant]
WO 2014099523A1 · 2014 [cited by applicant]
WO 2014164777A1 · 2014 [cited by applicant]
WO 2014194032A1 · 2014 [cited by applicant]
WO 2014194117A2 · 2014 [cited by applicant]
WO 2015024739A2 · 2015 [cited by applicant]
WO 2015089441A1 · 2015 [cited by applicant]
WO 2015089447A1 · 2015 [cited by applicant]
WO 2015091989A1 · 2015 [cited by applicant]
WO 2015091990A1 · 2015 [cited by applicant]
WO 2015143360A2 · 2015 [cited by applicant]
WO 2015193488A1 · 2015 [cited by applicant]
WO 2016066756A2 · 2016 [cited by applicant]
WO 2016066757A2 · 2016 [cited by applicant]
WO 2016069557A1 · 2016 [cited by applicant]
WO 2016069563A1 · 2016 [cited by applicant]
WO 2016069569A2 · 2016 [cited by applicant]
WO 2016075078A2 · 2016 [cited by applicant]
WO 2016091688A1 · 2016 [cited by applicant]
WO 2016174234A2 · 2016 [cited by applicant]
WO 2016180748A1 · 2016 [cited by applicant]
WO 2016183509A1 · 2016 [cited by applicant]
WO 2017089093A1 · 2017 [cited by applicant]
WO 2017192657A1 · 2017 [cited by applicant]
WO 2017215925A1 · 2017 [cited by applicant]
WO 2018118950A1 · 2018 [cited by applicant]
WO 2020156419A1 · 2020 [cited by applicant]
WO 2020221578A1 · 2020 [cited by applicant]
WO 2020221579A1 · 2020 [cited by applicant]
WO 2020221580A1 · 2020 [cited by applicant]
WO 2020242858A1 · 2020 [cited by applicant]
WO 2021013687A1 · 2021 [cited by applicant]
WO 2021080948A2 · 2021 [cited by applicant]
WO 2021081547A2 · 2021 [cited by applicant]
PDF NCBI Reference Sequence ID: WP_143850013.1 first seen at NCBI on Jul. 31, 2019 (downloaded Jul. 22, 2025) (Year: 2019). [cited by examiner]
All Office Actions; U.S. Appl. No. 18/065,644, Dec. 14, 2022. [cited by applicant]
U.S. Appl. No. 18/065,644, filed Dec. 14, 2022, Michelle Jackson et al. [cited by applicant]
PCT Search Report and Written Opinion for PCT/US2022/081484 dated May 2, 2023, 15 pages. [cited by applicant]